IRIS
CASTAGNA, ANTONELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.220
EU - Europa 4.277
NA - Nord America 2.603
SA - Sud America 622
AF - Africa 54
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 7
Totale 12.794
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.524
SG - Singapore 1.861
CN - Cina 1.698
HK - Hong Kong 1.458
SE - Svezia 1.378
IT - Italia 712
RU - Federazione Russa 646
RO - Romania 603
BR - Brasile 563
DE - Germania 372
FI - Finlandia 186
AT - Austria 115
GB - Regno Unito 54
IE - Irlanda 54
IN - India 49
NL - Olanda 46
CA - Canada 45
PK - Pakistan 26
MX - Messico 23
AR - Argentina 22
FR - Francia 22
BE - Belgio 18
IQ - Iraq 16
IR - Iran 16
TR - Turchia 15
ID - Indonesia 14
LT - Lituania 14
MA - Marocco 13
EU - Europa 11
PH - Filippine 11
UA - Ucraina 11
ZA - Sudafrica 10
CO - Colombia 9
JP - Giappone 9
BD - Bangladesh 8
EC - Ecuador 8
EG - Egitto 8
ES - Italia 7
AU - Australia 6
DO - Repubblica Dominicana 6
KR - Corea 6
CL - Cile 5
KZ - Kazakistan 5
NG - Nigeria 5
PY - Paraguay 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
MD - Moldavia 4
NO - Norvegia 4
PL - Polonia 4
TN - Tunisia 4
UZ - Uzbekistan 4
AL - Albania 3
GE - Georgia 3
GT - Guatemala 3
HR - Croazia 3
PE - Perù 3
AZ - Azerbaigian 2
CH - Svizzera 2
HU - Ungheria 2
JO - Giordania 2
KE - Kenya 2
MW - Malawi 2
OM - Oman 2
RS - Serbia 2
TH - Thailandia 2
AO - Angola 1
BG - Bulgaria 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DZ - Algeria 1
ET - Etiopia 1
GH - Ghana 1
GR - Grecia 1
IL - Israele 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
ME - Montenegro 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
SA - Arabia Saudita 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
TZ - Tanzania 1
UY - Uruguay 1
VN - Vietnam 1
ZM - Zambia 1
ZW - Zimbabwe 1
Totale 12.794
Salva come PNG Salva come JPEG
Città #
Hong Kong 1.452
Shanghai 769
Singapore 603
Lawrence 542
Princeton 542
Shenzhen 434
Moscow 298
Milan 276
Ashburn 210
New York 207
Nuremberg 157
Helsinki 151
Boardman 101
Rome 54
Dublin 51
Guangzhou 49
Vienna 47
São Paulo 46
Cesano Boscone 39
Falkenstein 39
Washington 34
Beijing 32
Lappeenranta 32
Pune 30
Seattle 27
Dallas 26
St Petersburg 24
Los Angeles 22
Belo Horizonte 19
Gatchina 18
Rio de Janeiro 18
Toronto 17
Brussels 15
London 15
Brescia 14
Genoa 14
Reston 14
Turin 14
Kassel 13
Amsterdam 12
Perm 12
Jiaxing 11
Mexico City 11
Ottawa 11
Porto Alegre 11
Quanzhou 11
Borås 10
Campinas 10
Curitiba 10
Padova 10
Santa Clara 10
Brasília 9
Lahore 9
Wuxi 9
Xi'an 9
Frankfurt am Main 8
Hanover 8
Paris 8
Yekaterinburg 8
Baghdad 7
Bologna 7
Jakarta 7
Pisa 7
Sorocaba 7
Busto Arsizio 6
Florence 6
Guarulhos 6
Istanbul 6
Munich 6
Nizhniy Novgorod 6
Quito 6
Voronezh 6
Campodolcino 5
Clifton 5
Hangzhou 5
Iztapalapa 5
Johannesburg 5
Madrid 5
Manassas 5
Maringá 5
Palmas 5
Romagnano Sesia 5
Salvador 5
Vittoria 5
Yongin-si 5
Almaty 4
Asunción 4
Bauru 4
Betim 4
Chengdu 4
Chisinau 4
Contagem 4
Cuiabá 4
Ferrara 4
Fremont 4
Fuzhou 4
Hyderabad 4
Karachi 4
Liverpool 4
Monsummano Terme 4
Totale 6.870
Salva come PNG Salva come JPEG
Nome #
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population 425
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 325
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres 214
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 199
Viral bloodstream detection in mpox patients: An observational multicentric study 142
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 89
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 75
Impact of Levofloxacin for Prophylaxis of Pre-engraftment Bloodstream Infections after Allogeneic HSCT: A single-center Matched Analysis in an Endemic Country for Carbapenem-resistant Gram-negative Bacteria 73
Gas-exchange deficit and systemic hypoperfusion in COVID-19 and non-COVID-19 young adult patients with pneumonia 69
Week 96 safety and efficacy of the novel HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced participants infected with multi-drug resistant HIV-1 (BRIGHTE study) 61
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency 60
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia 59
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 58
T and B cell responses to cytomegalovirus antigens in healthy blood donors and bone marrow transplant recipients 57
Testosterone in males with COVID-19: A twelve-month cohort study 53
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 48
Biobanking for COVID-19 research 47
Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study 47
Continuous positive airway pressure and pronation outside the Intensive Care Unit in COVID-19 acute respiratory distress syndrome 46
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 44
Levofloxacin prophylaxis vs no prophylaxis in neutropenic patients within an endemic country for carbapenem-resistant GNB 43
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 42
Predictors of survival in elderly patients with coronavirus disease 2019 admitted to the hospital: derivation and validation of the FLAMINCOV score 42
Response to combination antiretroviral therapy: Variation by age 42
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 41
Combined plasma levels of IL-10 and testosterone, but not soluble HLA-G5, predict the risk of death in COVID-19 patients 39
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 39
Subclinical myocardial dysfunction in patients recovered from COVID-19 38
Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia 37
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 36
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threating Features Within the Early Post-engraftment Phase 36
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 36
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 35
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 34
Pulmonary Vascular Thrombosis in COVID-19 Pneumonia 34
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 34
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 34
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 33
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier 33
Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression who switched to a different antiretroviral regimen 33
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy 33
Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis 33
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial 32
Antibiotic appropriateness for Gram-negative bloodstream infections: impact of infectious disease consultation 32
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 32
Compassionate use of remdesivir for patients with severe Covid-19 32
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 32
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 31
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 31
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 31
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 31
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 31
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 31
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 31
Symptoms and signs of conjunctivitis as predictors of disease course in COVID-19 syndrome 31
Profiling Covid-19 patients with respect to level of severity: an integrated statistical approach 30
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium 30
INCREASED RISK OF DEATH AMONG HIV/HCV CO-INFECTED PATIENTS WITH NON-HODGKIN'S LYMPHOMA 30
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 30
Switching antiretrovirals in older patients 30
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 30
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 30
Severely low testosterone in males with COVID-19: a case-control study 30
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 30
Post-neurosurgical Nocardia meningoventriculitis: a case report and review of the literature 29
A follow-up study in asymptomatic HIV patients 29
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike Receptor Binding Domain 29
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 29
Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study 29
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 28
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 28
Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption 28
LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples 28
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 28
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial 28
Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching 28
Fostemsavir in adults with multidrug-resistant HIV-1 infection 28
PS1268 CEFTAZIDIME/AVIBACTAM AND CEFTOLOZANE/TAZOBACTAM FOR THE TREATMENT OF FEBRILE NEUTROPENIA IN ALLOGENEIC TRANSPLANT RECIPIENTS 28
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 28
A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults 28
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 28
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 27
Beyond stigma: Monkeypox infection in a 27-year-old woman 27
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 27
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial 27
Cerebrospinal fluid beta 2-microglobulin in AIDS related central nervous system involvement. 27
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 27
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 27
Rhodococcus defluvii pneumonia: First reported case in humans 27
Rugarli. Medicina interna sistematica 27
Role of blood pressure dysregulation on kidney and mortality outcomes in COVID-19. Kidney, blood pressure and mortality in SARS-CoV-2 infection 27
Testosterone in males with COVID-19: A 7-month cohort study 27
Erratum: Correction to: Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV (BMC infectious diseases (2021) 21 1 (557)) 27
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium 27
Probable West Nile Virus hepatitis: Case report 26
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial 26
Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy 26
Therapeutic trials with HPA23, alpha-IFN and ribavirin in AIDS patients 26
Bictegravir 26
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 26
Totale 4.664
Salva come PNG Salva come JPEG
Categoria #
all - tutte 176.096
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.096
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 0 0 0 1 1
2020/2021235 2 0 1 23 0 51 11 131 5 0 7 4
2021/2022417 1 0 0 137 26 29 36 64 36 29 16 43
2022/20232.833 1.206 552 220 27 36 257 174 185 98 19 35 24
2023/20242.159 45 66 641 171 178 408 59 180 8 45 113 245
2024/20257.713 1.077 150 178 281 363 850 1.844 776 1.365 829 0 0
Totale 13.787